Restaging

OTHER2 trials

Sponsors

Robert Redner, MD, Yanhong Deng

Conditions

MyelomaRectal Cancer

Phase 1

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

CompletedNCT01042704

Robert Redner, MDMyeloma

Start: 2008-02-29End: 2015-03-31Updated: 2017-07-31

Phase 3

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

RecruitingNCT04215731

Yanhong DengRectal Cancer

Start: 2020-03-27End: 2029-06-01Target: 582Updated: 2026-03-03

Related Papers

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

2012-03-2688 citations